<DOC>
	<DOCNO>NCT00516893</DOCNO>
	<brief_summary>The primary objective study evaluate immunogenicity natalizumab ( TysabriÂ® ) produce modified manufacturing process ( natalizumab high titer ; BG00002-E ) administer intravenously ( IV ) participant relapse form multiple sclerosis ( MS ) . The secondary objective study evaluate safety natalizumab high titer .</brief_summary>
	<brief_title>Natalizumab High Titer Immunogenicity Safety</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Diagnosis relapse form MS Must fall within therapeutic indication state locally approve label natalizumab Other protocoldefined inclusion criterion may apply Prior treatment natalizumab Considered investigator immunocompromised Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>natalizumab</keyword>
	<keyword>Tysabri</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing Forms Multiple Sclerosis</keyword>
</DOC>